Literature DB >> 9563477

The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation.

H Fan1, C Villegas, A Huang, J A Wright.   

Abstract

Ribonucleotide reductase, which is composed of the two protein components R1 and R2, is a highly regulated enzyme activity that is essential for DNA synthesis and repair. Recent studies have shown that elevated expression of the rate-limiting R2 component increases Raf-1 protein activation and mitogen-activated protein kinase activity and acts as a novel malignancy determinant in cooperation with H-ras and rac-1. We show that R2 cooperation in cellular transformation extends to a variety of oncogenes with different functions and cellular locations. Anchorage-independent growth of cells transformed with v-fms, v-src, A-raf, v-fes, c-myc, and ornithine decarboxylase was markedly enhanced when the R2 component of ribonucleotide reductase was overexpressed. In addition, we observed that elevated R2 expression conferred on c-myc-transformed NIH 3T3 cells an increased tumorigenic potential in immunoincompetent mice. Taken together, these observations demonstrate that the R2 protein is not only a rate-limiting component for ribonucleotide reduction but that it is also capable of acting in cooperation with a variety of oncogenes to determine transformation and tumorigenic potential.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563477

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Gene expression profiles of human breast cancer progression.

Authors:  Xiao-Jun Ma; Ranelle Salunga; J Todd Tuggle; Justin Gaudet; Edward Enright; Philip McQuary; Terry Payette; Maria Pistone; Kimberly Stecker; Brian M Zhang; Yi-Xiong Zhou; Heike Varnholt; Barbara Smith; Michelle Gadd; Erica Chatfield; Jessica Kessler; Thomas M Baer; Mark G Erlander; Dennis C Sgroi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-24       Impact factor: 11.205

2.  Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.

Authors:  Allyson J Ocean; Paul Christos; Joseph A Sparano; Dan Matulich; Andreas Kaubish; Abby Siegel; Max Sung; Maureen M Ward; Nancy Hamel; Igor Espinoza-Delgado; Yun Yen; Maureen E Lane
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-28       Impact factor: 3.333

3.  Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.

Authors:  Rebecca B Klisovic; William Blum; Zhongfa Liu; Zhiliang Xie; Cheryl Kefauver; Lenguyen Huynh; James A Zwiebel; Steven M Devine; John C Byrd; Michael R Grever; Kenneth K Chan; Guido Marcucci
Journal:  Leuk Lymphoma       Date:  2013-11-01

4.  Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress.

Authors:  Ilya N Kotov; Ellen Siebring-van Olst; Philip A Knobel; Ida H van der Meulen-Muileman; Emanuela Felley-Bosco; Victor W van Beusechem; Egbert F Smit; Rolf A Stahel; Thomas M Marti
Journal:  Mol Oncol       Date:  2014-07-22       Impact factor: 6.603

5.  The future in advanced prostate cancer: take your partners or is the last dance for me?

Authors:  David I Quinn
Journal:  Rev Urol       Date:  2004

6.  A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.

Authors:  Mark H Kirschbaum; Paul Frankel; Timothy W Synold; Zhiliang Xie; Yun Yen; Leslie Popplewell; Robert Chen; Omar Aljitawi; Joseph M Tuscano; Kenneth K Chan; Edward M Newman
Journal:  Leuk Lymphoma       Date:  2016-02-19

7.  Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.

Authors:  Charles A Kunos; Song-mao Chiu; John Pink; Timothy J Kinsella
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

8.  A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.

Authors:  Natasha B Leighl; Scott A Laurie; Xueyu E Chen; Peter Ellis; Frances A Shepherd; Jennifer J Knox; Glenwood Goss; Ronald L Burkes; Gregory R Pond; Christopher Dick; Yun Yen; James A Zwiebel; Malcolm J Moore
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

9.  Counteraction of pRb-dependent protection after extreme hypoxia by elevated ribonucleotide reductase.

Authors:  P Graff; J Seim; Ø Amellem; H Arakawa; Y Nakamura; K K Andersson; T Stokke; E O Pettersen
Journal:  Cell Prolif       Date:  2004-10       Impact factor: 6.831

10.  Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.

Authors:  Keqiang Zhang; Shuya Hu; Jun Wu; Linling Chen; Jianming Lu; Xiaochen Wang; Xiyong Liu; Bingsen Zhou; Yun Yen
Journal:  Mol Cancer       Date:  2009-02-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.